CytomX Therapeutics (CTMX) Q3 FY2024 earnings: revenue $33 million, up 26.7% on the year
CytomX Therapeutics, Inc. (CTMX) reported revenue of $33 million for Q3 FY2024, the quarter ended 30 September 2024, up 26.7% on the same quarter a year earlier. Net income was $6 million, up 91.7% on the year, and diluted earnings per share $0.07. The figures are the company's own, from the 10-Q it filed with the SEC on 7 November 2024.
Revenue$33 millionup 26.7%
Net income$6 millionup 91.7%
Diluted EPS$0.07
QuarterQ3 FY2024ended 30 September 2024
The quarter, against the one before and a year earlier
| Line | Q3 FY2024 | Q2 FY2024 | Q3 FY2023 | Change on the year |
|---|---|---|---|---|
| Revenue | 33.4 | 25.1 | 26.4 | +26.7% |
| Research and development | 21.4 | 25.2 | 16.4 | +29.9% |
| Operating income | 4.1 | -8.5 | 3.1 | +31.6% |
| Operating margin | 12.3% | -33.7% | 11.8% | |
| Pre-tax income | 5.8 | -6.5 | 5.8 | -0.3% |
| Income tax | 0.1 | 0.1 | 2.8 | -97.8% |
| Effective tax rate | 1.1% | n/a | 48.5% | |
| Net income | 5.7 | -6.5 | 3.0 | +91.7% |
| Net margin | 17.2% | -26.0% | 11.3% | |
| Diluted EPS | $0.07 | -$0.08 | $0.04 | +75.0% |
$ million except per share.
Read more
Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.Cash flow and capital returned
| Line | Q3 FY2024 | Q2 FY2024 | Q3 FY2023 | Change on the year |
|---|---|---|---|---|
| Operating cash flow | -20.7 | -19.5 | -18.2 | n/a |
| Capital expenditure | 0.0 | 0.1 | 0.0 | +111.1% |
| Free cash flow | -20.7 | -19.6 | -18.3 | n/a |
| Free cash flow margin | -62.1% | -78.2% | -69.2% | |
| Cash from investing | 18.2 | 21.5 | -42.9 | n/a |
| Cash from financing | 0.0 | 5.1 | 29.7 | n/a |
| Share-based compensation | 2.0 | 1.9 | 1.2 | +62.7% |
| Diluted shares, weighted | 85m | 85m | 81m | +5.2% |
| Shares outstanding at period end | 78m | 78m | 67m | +16.8% |
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet at quarter end
| Line | Q3 FY2024 | Q2 FY2024 | Q3 FY2023 | Change on the year |
|---|---|---|---|---|
| Shareholders' equity | -23.5 | -31.2 | -51.2 | n/a |
| Debt | 0.0 | 0.0 | 0.0 | n/a |
| Operating lease liabilities | 5.6 | 6.9 | 10.6 | -47.2% |
| Other liabilities | 157 | 184 | 262 | -40.1% |
| Total liabilities and equity | 139 | 159 | 221 | -37.2% |
| Fixed assets | 2.9 | 3.3 | 4.1 | -27.5% |
| Goodwill | 0.9 | 0.9 | 0.9 | +0.0% |
| Investments | 77.0 | 93.9 | 168 | -54.2% |
| Cash and equivalents | 40.6 | 43.2 | 26.0 | +55.9% |
| Receivables | 3.4 | 2.8 | 2.4 | +38.6% |
| Other assets | 14.2 | 15.0 | 19.6 | -27.9% |
| Total assets | 139 | 159 | 221 | -37.2% |
Questions
What was CytomX Therapeutics' revenue in Q3 FY2024?
CytomX Therapeutics (CTMX) reported revenue of $33 million for Q3 FY2024, the quarter ended 30 September 2024, up 26.7% on the same quarter a year earlier.
How much did CytomX Therapeutics earn in Q3 FY2024?
Net income for Q3 FY2024 was $6 million, up 91.7% on the year, and diluted earnings per share $0.07.
When did CytomX Therapeutics report Q3 FY2024 results?
CytomX Therapeutics filed its 10-Q for the quarter ended 30 September 2024 with the SEC on 7 November 2024.
Quarterly results, the last 20 quarters
| Q3 FY2021 † | Q4 FY2021 * | Q1 FY2022 † | Q2 FY2022 † | Q3 FY2022 † | Q4 FY2022 * | Q1 FY2023 | Q2 FY2023 | Q3 FY2023 | Q4 FY2023 * | Q1 FY2024 | Q2 FY2024 | Q3 FY2024 | Q4 FY2024 * | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 * | Q1 FY2026 | Q2 FY2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.6 | 19.7 | 9.0 | 12.9 | 11.1 | 20.1 | 23.5 | 24.7 | 26.4 | 26.6 | 41.5 | 25.1 | 33.4 | 38.1 | 50.9 | 18.7 | 6.0 | 0.7 | 10.3 | 1.4 |
| R&D | 29.1 | 36.6 | 30.6 | 31.2 | 30.4 | 19.6 | 21.2 | 20.7 | 16.4 | 19.4 | 22.1 | 25.2 | 21.4 | 14.8 | 18.9 | 13.3 | 15.3 | 21.2 | 19.2 | 17.6 |
| Operating income | -31.0 | -34.9 | -32.1 | -30.1 | -29.7 | -9.5 | -5.7 | -3.3 | 3.1 | -0.6 | 11.7 | -8.5 | 4.1 | 17.7 | 22.6 | -1.3 | -15.8 | -27.9 | -19.7 | -23.8 |
| Operating margin | -176% | -177% | -355% | -234% | -267% | -47% | -24% | -14% | 12% | -2% | 28% | -34% | 12% | 46% | 44% | -7% | -264% | -4213% | -192% | -1677% |
| Pre-tax income | -31.0 | -34.8 | -32.0 | -29.5 | -29.1 | n/a | -3.3 | -1.1 | 5.8 | 1.9 | 13.8 | -6.5 | 5.8 | 18.9 | 23.6 | -0.1 | -14.2 | -26.5 | -18.2 | -20.6 |
| Tax rate | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 49% | 56% | 0% | n/a | 1% | 0% | 0% | n/a | n/a | n/a | n/a | n/a |
| Net income | -31.0 | -34.8 | -32.0 | -29.5 | -29.1 | -8.8 | -3.3 | -1.1 | 3.0 | 0.8 | 13.8 | -6.5 | 5.7 | 18.9 | 23.5 | -0.2 | -14.2 | -26.5 | -18.2 | -20.7 |
| Net margin | -176% | -177% | -354% | -229% | -261% | -44% | -14% | -4% | 11% | 3% | 33% | -26% | 17% | 50% | 46% | -1% | -239% | -3998% | -178% | -1457% |
| Diluted EPS | -$0.35 | -$0.53 | -$0.49 | -$0.37 | -$0.35 | -$0.30 | -$0.05 | -$0.02 | $0.04 | $0.02 | $0.17 | -$0.08 | $0.07 | n/a | $0.27 | $0.00 | -$0.09 | n/a | -$0.10 | -$0.09 |
| Operating cash flow | -29.7 | -31.2 | -41.3 | -34.2 | -33.8 | -1.4 | 9.3 | -25.2 | -18.2 | -22.0 | -26.0 | -19.5 | -20.7 | -19.9 | -21.0 | -15.8 | -15.5 | -23.2 | -25.5 | -18.1 |
| Capital expenditure | 0.3 | 0.2 | 0.7 | 0.4 | 0.4 | 0.2 | 0.0 | 0.5 | 0.0 | 0.3 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | 0.0 | n/a | 0.2 | 0.0 | 0.0 |
| Free cash flow | -30.0 | -31.4 | -42.0 | -34.6 | -34.3 | -1.6 | 9.3 | -25.7 | -18.3 | -22.2 | -26.2 | -19.6 | -20.7 | -20.0 | -21.2 | -15.8 | n/a | -23.4 | -25.5 | -18.1 |
| Shares outstanding | 65m | 65m | 65m | 66m | 66m | 66m | 66m | 67m | 67m | 67m | n/a | 78m | 78m | 80m | 81m | 165m | 169m | 170m | 218m | 218m |
| Filing | 10-Q | 10-K | 10-K | 10-K | 10-K | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
Each quarter as filed, linked to its filing.
Read more
* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A blank figure marked on a quarter is one the filings do not give on their own: the quarters as filed do not add to the year the company filed, or the year and its quarters stand on different share counts. Each quarter's page says which. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.10-Q for the period ended 30 September 2024, filed 7 November 2024: the filing.